000282966 001__ 282966
000282966 005__ 20251219150319.0
000282966 0247_ $$2doi$$a10.1093/braincomms/fcaf467
000282966 0247_ $$2pmid$$apmid:41416250
000282966 0247_ $$2pmc$$apmc:PMC12709281
000282966 037__ $$aDZNE-2025-01418
000282966 041__ $$aEnglish
000282966 082__ $$a610
000282966 1001_ $$00000-0002-7786-2747$$aShapiro, Noah L$$b0
000282966 245__ $$aInflammation PET and plasma neurofilament light predict survival in people with progressive supranuclear palsy.
000282966 260__ $$a[Oxford]$$bOxford University Press$$c2025
000282966 3367_ $$2DRIVER$$aarticle
000282966 3367_ $$2DataCite$$aOutput Types/Journal article
000282966 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766152894_31935
000282966 3367_ $$2BibTeX$$aARTICLE
000282966 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000282966 3367_ $$00$$2EndNote$$aJournal Article
000282966 520__ $$aProgressive supranuclear palsy (PSP) is a primary tauopathy characterized by atrophy and neuroinflammation of the brainstem, the basal ganglia and, to a lesser degree, the cortex. This study investigates the association of regional atrophy (structural MRI), neuroinflammation ([11C]-PK11195 PET), peripheral markers of neurodegeneration [plasma neurofilament light chain (NfL)] and clinical severity [PSP rating scale (PSPRS)] with survival in people with PSP. Fifty-nine people with PSP underwent longitudinal structural MRI, surviving on average 3.2 years from the first scan (MRI cohort). Sixteen participants (PET cohort) within this cohort underwent cross-sectional [11C]-PK11195 PET and blood sampling for plasma NfL. We applied modality-specific principal component analyses on imaging data and ran partial correlations, multivariate regressions and Bayesian models to evaluate the association between survival and imaging patterns, clinical severity and plasma NfL. In the PET cohort, higher levels of localized inflammation in subcortical regions [rho = -0.49, P = 0.02, Bayes factor (BF) = 8.07] and plasma NfL (rho = -0.57, P = 0.01, BF = 4.63) were associated with shorter survival, while PSPRS scores were not significant predictors of survival. Subcortical atrophy was associated with shorter survival in the larger cohort (r = -0.38, P = 0.001; β = -0.66, P = 0.001). Spearman's correlations, multivariate regressions and Bayesian models converged to the same results. Regional subcortical atrophy is a robust biomarker associated with survival in people with PSP that can be utilized in large-scale clinical trials. Translocator protein (TSPO) PET and plasma NfL offer promising complementary markers for smaller-scale trials, where they may prove more sensitive than clinical scores or structural MRI alone. By linking neuroinflammation to survival, our results also highlight immunotherapy as a promising avenue for disease-modifying treatment in PSP.
000282966 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000282966 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000282966 650_7 $$2Other$$aPET NfL
000282966 650_7 $$2Other$$aneuroinflammation
000282966 650_7 $$2Other$$aprogressive supranuclear palsy
000282966 650_7 $$2Other$$asurvival
000282966 7001_ $$aJones, Peter Simon$$b1
000282966 7001_ $$00000-0002-6437-8024$$aMak, Elijah$$b2
000282966 7001_ $$aTsvetanov, Kamen A$$b3
000282966 7001_ $$aGoddard, Julia$$b4
000282966 7001_ $$aVontobel, Davi S$$b5
000282966 7001_ $$00000-0001-9870-0117$$aDurcan, Robert$$b6
000282966 7001_ $$00000-0002-3052-3879$$aChouliaras, Leonidas$$b7
000282966 7001_ $$aFryer, Tim$$b8
000282966 7001_ $$aHong, Young T$$b9
000282966 7001_ $$aAigbirhio, Franklin$$b10
000282966 7001_ $$aHeslegrave, Amanda$$b11
000282966 7001_ $$00000-0001-9736-2283$$aFranzmeier, Nicolai$$b12
000282966 7001_ $$0P:(DE-2719)9001539$$aBrendel, Matthias$$b13
000282966 7001_ $$aZetterberg, Henrik$$b14
000282966 7001_ $$00000-0002-0837-5080$$aO'Brien, John T$$b15
000282966 7001_ $$aRowe, James B$$b16
000282966 7001_ $$00000-0001-8923-9656$$aMalpetti, Maura$$b17
000282966 773__ $$0PERI:(DE-600)3020013-1$$a10.1093/braincomms/fcaf467$$gVol. 7, no. 6, p. fcaf467$$n6$$pfcaf467$$tBrain communications$$v7$$x2632-1297$$y2025
000282966 8564_ $$uhttps://pub.dzne.de/record/282966/files/DZNE-2025-01418.pdf$$yRestricted
000282966 8564_ $$uhttps://pub.dzne.de/record/282966/files/DZNE-2025-01418.pdf?subformat=pdfa$$xpdfa$$yRestricted
000282966 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001539$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b13$$kDZNE
000282966 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000282966 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBRAIN COMMUN : 2022$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2024-04-03T10:36:45Z
000282966 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2024-04-03T10:36:45Z
000282966 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2024-04-03T10:36:45Z
000282966 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2024-04-03T10:36:45Z
000282966 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-20
000282966 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-20
000282966 9201_ $$0I:(DE-2719)1110007$$kAG Haass$$lMolecular Neurodegeneration$$x0
000282966 980__ $$ajournal
000282966 980__ $$aEDITORS
000282966 980__ $$aVDBINPRINT
000282966 980__ $$aI:(DE-2719)1110007
000282966 980__ $$aUNRESTRICTED